Drugs / Salmonella typhi vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01533285 | May 2012 → Nov 2013 | major depressive disorder | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02653235 Comparator | Jan → Sep 2016 | major depressive disorder | NHS Greater Glasgow and Clyde | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salmonella typhi vaccine | “We used a double-blind, crossover design to randomize 20 male subjects to receive either a Salmonella typhi vaccine or a placebo saline injection at two separate sessions.” PMID 32532687 ↗ Apr 2020 |
| Known as | Typhim Vi | “Salmonella typhi vaccine (Typhim Vi)” NCT01533285 ↗ |
| Modality | Vaccine | “Treatment B is typhoid vaccination” NCT01533285 ↗ |